Home Tags Eisai

Tag: Eisai

Japan – Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
Business

Japan – Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease

Correspondent -
0
Japan – Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status
Business

Japan – Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

Editor -
0
Japan – Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia
Business

Japan – Eisai Commences Business Activities At New Pharma Sales Subsidiary In Saudi Arabia

Correspondent -
0
Japan – Eisai Announces Status Relating to Acquisition of Own Shares
Business

Japan – Eisai Announces Status Relating to Acquisition of Own Shares

Editor -
0
Japan – Eisai Named to List of The Time 100 Most Influential Companies
Business

Japan – Eisai Named to List of The Time 100 Most Influential Companies

-
0
Japan – Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform
Business

Japan – Eisai Strengthens Venture Investment Business Aimed at Accelerating Drug Discovery Innovation and Establishment of Ecosystem Platform

-
0
Japan – Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
Business

Japan – Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024

-
0
Japan – Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan
Business

Japan – Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Launched In Japan

-
0
Japan – Eisai: Research on Treatments for Alzheimer’s Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)
Business

Japan – Eisai: Research on Treatments for Alzheimer’s Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)

-
0
Japan – Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA
Business

Japan – Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA

Editor -
0
Japan – Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical
Business

Japan – Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical

-
0
Japan – Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024
Business

Japan – Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024

-
0
Japan – Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace
Business

Japan – Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace

-
0
Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan
Business

Eisai: Metoject Subcutaneous Injection Pen (Methotrexate) Pen-Type Autoinjector Approved in Japan

-
0
Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa
Business

Eisai Commences Fully-Fledged Business Activities at Pharma Sales Subsidiary in South Africa

-
0
Japan – Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis
Business

Japan – Eisai Submits New Drug Application for Mecobalamin Ultrahigh-Dose Formulation in Japan for the Indication of Amyotrophic Lateral Sclerosis

-
0
Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan
Business

Eisai: Antiepileptic Drug Fycompa Injection Formulation Approved in Japan

-
0
Eisai: “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China
Business

Eisai: “LEQEMBI” (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in China

-
0
Japan – Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time
Business

Japan – Eisai Listed as a Global 100 Most Sustainable Corporation for the Eighth Time

Editor -
0
Japan – Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU
Business

Japan – Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU

-
0
Japan – Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion
Business

Japan – Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion

-
0
Japan – Eisai and Mizuho Sign Sustainability-Linked Loan Agreement
Business

Japan – Eisai and Mizuho Sign Sustainability-Linked Loan Agreement

-
0
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma
Business

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma

-
0
Eisai Launches New “Innovation” Page on Corporate Website
Business

Eisai Launches New “Innovation” Page on Corporate Website

-
0
Japan – Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023
Business

Japan – Eisai to Present Research from Oncology Portfolio and Pipeline at ESMO Congress 2023

-
0
Japan – Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.
Business

Japan – Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.

Editor -
0
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer’s Day, September 21
Business

Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer’s Day, September 21

-
0
Japan – Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Business

Japan – Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

-
0
Japan – Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer’s Disease in South Korea
Business

Japan – Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer’s Disease in South Korea

-
0
Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease in Great Britain
Business

Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease in Great Britain

-
0
Japan – Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration
Business

Japan – Eisai Enters Into Joint Development Agreement with Blissbio for Antibody Drug Conjugate BB-1701 with Option Rights for Strategic Collaboration

-
0
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
Business

Eisai Completes a Major Renovation of Tsukuba Research Laboratories

-
0
Japan – Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal
Business

Japan – Eisai Publishes Long-Term Health Outcomes Using Simulation Model of Lecanemab Using Phase 3 Clarity Ad Data in Peer-Reviewed Neurology and Therapy Journal

-
0
Japan – Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on “Patient-Proposed Healthcare Services” System
Business

Japan – Eisai Enters Into Agreement With National Cancer Center to Collaborate on Investigator-Initiated Clinical Research for Anticancer Agent Tazemetostat Based on “Patient-Proposed Healthcare Services” System

-
0
Japan – Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals
Business

Japan – Eisai: Additional Detailed Analyses from Phase 2 Study 201 of Lecanemab Published as Three Papers in Peer-Reviewed Journals

-
0
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer
Business

Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer

-
0
Japan – Eisai Receives the “Basic Achievement Grand Prize” at the 2023 J-Win Diversity Award
Business

Japan – Eisai Receives the “Basic Achievement Grand Prize” at the 2023 J-Win Diversity Award

-
0
Eisai Certified as a 2023 Health and Productivity Management Outstanding
Business

Eisai Certified as a 2023 Health and Productivity Management Outstanding

Editor -
0
Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
Business

Eisai: Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency

Editor -
0
Japan – Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel
Business

Japan – Eisai Commences Business Activities at New Pharma Sales Subsidiary in Israel

-
0
Japan – Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company
Business

Japan – Eisai Listed as a Global 100 Most Sustainable Corporation for The Seventh Time Highest Ranked Global Pharmaceutical Company

-
0
Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan
Business

Eisai Files Marketing Authorization Application for Anti-Amyloid-Beta Protofibril Antibody Lecanemab for Early Alzheimer’s Disease in Japan

-
0
Japan – Eisai Launches Renewed Sustainability Page
Business

Japan – Eisai Launches Renewed Sustainability Page

-
0
Japan – Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease in Europe
Business

Japan – Eisai Submits Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease in Europe

-
0
Japan – Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
Business

Japan – Eisai Submits Supplemental Biologics License Application to FDA for Traditional Approval of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer’s Disease

Editor -
0
Japan – Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Business

Japan – Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging

Editor -
0
Japan – Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
Business

Japan – Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals

Editor -
0
Japan – Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases
Business

Japan – Eisai and Washington University School of Medicine in St. Louis Enter Into Comprehensive Research Collaboration Agreement Aiming to Create New Therapies for Neurodegenerative Diseases

-
0
Japan – Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium
Business

Japan – Eisai to Present Preclinical and Clinical Research on Eribulin at the 2022 San Antonio Breast Cancer Symposium

-
0
Japan – Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH
Business

Japan – Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH

-
0
Japan – Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination
Business

Japan – Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination

-
0
Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon
Business

Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon

-
0
Japan – Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis
Business

Japan – Eisai: Metoject Subcutaneous Injection Syringe (Methotrexate) Approved in Japan for Rheumatoid Arthritis

-
0
Japan – Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma
Business

Japan – Eisai and Merck & Co., Inc. Present Results from Phase 3 LEAP-002 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

-
0
Japan – Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022
Business

Japan – Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022

-
0
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series
Business

Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series

-
0
Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022
Business

Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022

-
0
Japan – Eisai Signs the Public-Private Partnership “Kigali Declaration” for Eliminating Neglected Tropical Diseases
Business

Japan – Eisai Signs the Public-Private Partnership “Kigali Declaration” for Eliminating Neglected Tropical Diseases

-
0
Japan – Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting
Business

Japan – Eisai Presents New Findings for Antibody Drug Conjugate Farletuzumab Ecteribulin at 2022 ASCO Annual Meeting

-
0
Japan – Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
Business

Japan – Eisai Contributes to the Science of Cancer Medicine at ASCO 2022

-
0
Japan – Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS
Business

Japan – Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS

-
0
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
Business

Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

-
0
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan
Business

Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan

-
0
Japan – Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen
Business

Japan – Eisai: Economic Arrangements of Amendment to Alzheimer’s Disease Treatment Collaboration Agreement with Biogen

-
0
Japan – Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease Treatments
Business

Japan – Biogen and Eisai Amend Collaboration Agreements on Alzheimer’s Disease Treatments

-
0
Japan – Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500)
Business

Japan – Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500)

-
0
Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab
Business

Eisai Initiates Submission of Application Data Under the Prior Assessment Consultation System in Japan with the Aim of Obtaining Early Approval for Investigational Anti-Amyloid Beta Protofibril Antibody Lecanemab

-
0
Japan – Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021
Business

Japan – Eisai Receives the Tokyo Governor Prize for Corporate Governance of the Year 2021

-
0
Japan – Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM
Business

Japan – Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM

-
0
Japan – Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases
Business

Japan – Eisai Announces Results and Continued Support of Initiatives for Elimination of Neglected Tropical Diseases

-
0
Japan – Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time
Business

Japan – Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time

-
0
Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma
Business

Eisai: Results From Pivotal Phase 3 Study 309/KEYNOTE-775 Trial of LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) in Advanced Endometrial Carcinoma

-
0
Japan – Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
Business

Japan – Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

-
0
Japan – Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia
Business

Japan – Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia

-
0
Japan – Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium
Business

Japan – Eisai to Present Abstracts on Oncology Products And Pipeline at 44th Annual San Antonio Breast Cancer Symposium

-
0
Japan – Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
Business

Japan – Eisai and FCNT Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia

-
0
Japan – Eisai Receives the ‘Most Liked!’ IR Award at The 2021 IR Award
Business

Japan – Eisai Receives the ‘Most Liked!’ IR Award at The 2021 IR Award

-
0
Japan – Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease
Business

Japan – Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease

-
0
Japan – Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference
Business

Japan – Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference

-
0
Japan – Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease
Business

Japan – Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease

-
0
Japan – Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study
Business

Japan – Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study

-
0
Japan – Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer’s Disease Under the Accelerated Approval Pathway
Uncategorized

Japan – Eisai Initiates Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab (BAN2401) for Early Alzheimer’s Disease Under the Accelerated Approval Pathway

-
0
Japan – Eisai to Join The Global Environmental Initiative “RE100”
Uncategorized

Japan – Eisai to Join The Global Environmental Initiative “RE100”

-
0
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021
Uncategorized

Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021

-
0
Japan – Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries
Uncategorized

Japan – Eisai and FUJI YAKUHIN Conclude License Agreement Concerning the Development and Distribution of Dotinurad in Five ASEAN Countries

-
0
Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)
Uncategorized

Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab (BAN2401)

-
0
Japan – Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment
Uncategorized

Japan – Eisai Listed for 20th Consecutive Year in FTSE4Good Index Series, An Index for Socially Responsible Investment

-
0
Japan – Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021
Uncategorized

Japan – Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021

-
0
Japan – Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong
Uncategorized

Japan – Eisai Launches In-house Developed Anti-insomnia Drug Dayvigo (Lemborexant) In Hong Kong

-
0
Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)
Uncategorized

Eisai and Biogen Inc. Announce U.S. FDA Grants Breakthough Therapy Designation for Lecanemab (BAN2401)

-
0
Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate
Uncategorized

Eisai, Bristol Myers Squibb Enter Into Global Strategic Collaboration for Eisai’s MORAb-202 Antibody Drug Conjugate

-
0
Japan – Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma
Uncategorized

Japan – Eisai to Divest Rights for Zonegran in Europe and Other Regions to Advanz Pharma

-
0
Japan – Eisai Receives Special Prize at Platinum Career Award 2021
Uncategorized

Japan – Eisai Receives Special Prize at Platinum Career Award 2021

-
0
Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia
Uncategorized

Eisai and ITO EN Enter Into Business Alliance Aiming to Support People Living with Dementia and to Prevent Dementia

-
0
Japan – Eisai and National Cancer Center Commence Joint Research and Development Project
Uncategorized

Japan – Eisai and National Cancer Center Commence Joint Research and Development Project

-
0
Japan – Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan
Uncategorized

Japan – Eisai: Application Submitted for Additional Indication of Anti Cancer Agent Lenvima in Combination With Keytruda as a Treatment for Advanced Uterine Body Cancer in Japan

-
0
Japan – Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease
Uncategorized

Japan – Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease

-
0
Japan – KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries
Uncategorized

Japan – KYORIN and Eisai Enter Into License Agreement Concerning the Development and Marketing of Vibegron, a Treatment for Overactive Bladder, in Four ASEAN Countries

-
0
Japan – Eisai: Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer
Uncategorized

Japan – Eisai: Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anti-Cancer Agent Lenvima (Lenvatinib) With Prospective Indication for Uterine Body Cancer

-
0
Japan – Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab
Uncategorized

Japan – Eisai: European Medicines Agency Accepts the Marketing Authorisation Applications for Two Additional Indications of Anti Cancer Agent Lenvatinib in Combination with Pembrolizumab

-
0
12Page 1 of 2
© Newspaper WordPress Theme by TagDiv